Takeda Pharmaceutical (TAK) Revenue (2017 - 2026)

Takeda Pharmaceutical's Revenue history runs 10 years deep, the most recent figure standing at $7.0 billion for Q1 2026.

• On a quarterly basis, Revenue fell 11.85% year-over-year to $7.0 billion in Q1 2026; TTM through Mar 2026 was $46.2 billion, a 0.21% change from a year earlier, with the FY2026 full-year figure at $29.9 billion, changed 0.48% from the prior year.
• Revenue retreated to $7.0 billion in Q1 2026 per TAK's latest filing, from $7.1 billion in the prior quarter.
• Across five years, Revenue topped out at $23.9 billion in Q3 2025 and bottomed at $6.9 billion in Q4 2024.
• The 5-year median for Revenue is $7.8 billion (2022), against an average of $10.4 billion.
• Across the five-year window, Revenue declined 13.32% in 2022 and jumped 206.56% in 2023, its largest moves.
• Year by year, Revenue stood at $7.8 billion in 2022, then declined by 8.4% to $7.1 billion in 2023, then dropped by 2.54% to $6.9 billion in 2024, then rose by 2.64% to $7.1 billion in 2025, then retreated by 1.86% to $7.0 billion in 2026.
• Per Business Quant, the three latest TAK Revenue figures stand at $7.0 billion (Q1 2026), $7.1 billion (Q4 2025), and $23.9 billion (Q3 2025).